Exelixis

Blue Faery: The Adrienne Wilson Liver Cancer Association

AA

A A

Exelixis

Print Friendly, PDF & Email

Exelisis

 

 

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, they established a broad drug discovery and development platform that has served as the foundation for their continued efforts to bring new cancer therapies to patients in need. Exelisis discovered their three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from their marketed products and collaborations, they are committed to prudently reinvesting in their business to maximize the potential of their pipeline. /They are supplementing their existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Scroll Up